79 related articles for article (PubMed ID: 38683491)
1. Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells.
Fischer MA; Mustafa AM; Hausmann K; Ashry R; Kansy AG; Liebl MC; Brachetti C; Piée-Staffa A; Zessin M; Ibrahim HS; Hofmann TG; Schutkowski M; Sippl W; Krämer OH
J Adv Res; 2024 Jun; 60():201-214. PubMed ID: 37467961
[TBL] [Abstract][Full Text] [Related]
2. In-silico design of novel potential HDAC inhibitors from indazole derivatives targeting breast cancer through QSAR, molecular docking and pharmacokinetics studies.
Pandiyan S; Wang L
Comput Biol Chem; 2024 Jun; 110():108035. PubMed ID: 38460437
[TBL] [Abstract][Full Text] [Related]
3. Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation.
Khadempar S; Lotfi M; Haghiralsadat F; Saidijam M; Ghasemi N; Afshar S
Comput Biol Med; 2023 Nov; 166():107518. PubMed ID: 37806058
[TBL] [Abstract][Full Text] [Related]
4. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
Desai D; Salli U; Vrana KE; Amin S
Bioorg Med Chem Lett; 2010 Mar; 20(6):2044-7. PubMed ID: 20167479
[TBL] [Abstract][Full Text] [Related]
5. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
Kemp MM; Wang Q; Fuller JH; West N; Martinez NM; Morse EM; Weïwer M; Schreiber SL; Bradner JE; Koehler AN
Bioorg Med Chem Lett; 2011 Jul; 21(14):4164-9. PubMed ID: 21696956
[TBL] [Abstract][Full Text] [Related]
6. Exploring different classification-dependent QSAR modelling strategies for HDAC3 inhibitors in search of meaningful structural contributors.
Jha T; Jana R; Banerjee S; Baidya SK; Amin SA; Gayen S; Ghosh B; Adhikari N
SAR QSAR Environ Res; 2024 May; 35(5):367-389. PubMed ID: 38757181
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.
Huff SE; Mohammed FA; Yang M; Agrawal P; Pink J; Harris ME; Dealwis CG; Viswanathan R
J Med Chem; 2018 Feb; 61(3):666-680. PubMed ID: 29253340
[TBL] [Abstract][Full Text] [Related]
8. Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents.
Martino E; Thakur S; Kumar A; Yadav AK; Boschi D; Kumar D; Lolli M
Mini Rev Med Chem; 2024 Jun; ():. PubMed ID: 38859778
[TBL] [Abstract][Full Text] [Related]
9. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
10. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities.
Shetty MG; Pai P; Dey B; Satyamoorthy K; Shil S; Nayak UY; T A; Sundara BK
Daru; 2024 Jun; 32(1):263-278. PubMed ID: 38683491
[TBL] [Abstract][Full Text] [Related]
12. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
13. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
14. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
15. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
